Novo Nordisk A/S
(NYSE : NVO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
1.15%42.150.9%$981.24m
MRKMerck & Co., Inc.
2.07%81.150.6%$802.54m
JNJJohnson & Johnson
0.42%138.700.7%$766.04m
BMYBristol-Myers Squibb Company
0.75%47.791.4%$673.19m
LLYEli Lilly and Company
1.38%118.191.0%$520.46m
ABBVAbbVie, Inc.
0.83%81.552.2%$453.03m
NVSNovartis AG Sponsored ADR
1.91%83.960.2%$212.34m
AZNAstraZeneca PLC Sponsored ADR
1.62%38.501.3%$191.76m
GSKGlaxoSmithKline plc Sponsored ADR
1.83%40.110.2%$100.38m
NVONovo Nordisk A/S Sponsored ADR Class B
1.96%48.460.1%$63.96m
SNYSanofi Sponsored ADR
2.33%42.140.2%$46.97m
LCILannett Company, Inc.
-0.82%6.0836.7%$10.07m
AKTXAkari Therapeutics Plc Sponsored ADR
-3.56%2.441.6%$3.45m
EPIXESSA Pharma Inc
-6.51%2.010.1%$0.01m

Company Profile

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the following segments: Diabetes & Obesity Care, and Biopharmaceuticals. The Diabetes & Obesity Care segment covers products for insulin; GLP-1 and related delivery systems; oral antidiabetic products; and obesity. The Biopharmaceuticals segment offers products for haemophilia; growth hormone therapy; and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.